The evolution of antibody-drug conjugates (ADCs) is a spectacular example of how global research can sculpt a new technology. Years of molecular and cell biology, conjugation chemistry and immunology progress has enabled a cytotoxic agent paired with a tumour-specifi c antibody to become mainstream cancer therapy.1 Today, advances continue, explains…
List view / Grid view
Product Hub: High sensitivity pyrogen testing with the PyroMAT™ system: make the move to the next MAT generation
18 December 2018 | By Merck
Used to detect a broad range of pyrogens in parenteral products including pharmaceuticals, biopharmaceuticals and medical devices, the Monocyte Activation Test (MAT) gives an in vitro alternative to conventional animal testing in accordance with regulatory guidelines.
17 December 2018 | By European Pharmaceutical Review
In this issue: Navigating roadblocks to clinical success: decision-making from molecule to clinic, Raman spectroscopy for the qualitative analysis of falsified and substandard medicines, and an overview of risk assessments for elemental impurities: implementation of ICH Q3D guidelines.
14 December 2018 | By European Pharmaceutical Review
Researchers have identified markers of pediatric acute lymphoblastic leukaemia to predict early relapses by testing levels of nucleotide excision repair...
13 December 2018 | By European Pharmaceutical Review
The FDA has provided guidance on data integrity and compliance; two areas extremely important for pharmaceutical businesses and manufacturers to adhere to...
12 December 2018 | By Thermo Fisher Scientific
Pharmaceutical companies that manufacture tablets, capsules, and other solid dosage forms use film coatings on their products to differentiate appearance and to improve palatability by masking unpleasant tastes or odors.
12 December 2018 | By Abbott Informatics
Most organisations that are looking to implement a new LIMS or replace an aging one have a significant investment in a number of information systems.
12 December 2018 | By IDBS
Many bioanalytical labs work with a crowded and siloed set of systems and processes. From part electronic to part paper-based workflows, to standalone point-solutions, the result is a lack of insight into data and slower reporting and results handling.
Whitepaper: Characterising antibody-drug conjugates using micro pillar array columns combined with mass spectrometry (μPAC™-MS)
12 December 2018 | By PharmaFluidics
The use of micro pillar array columns (μPAC™) for characterising antibody-drug-conjugates is presented. Kadcyla® (ado-trastuzumab emtansine) and, for comparison, Herceptin® (trastuzumab) tryptic digests were analysed on a 200 cm μPAC™ C18 column and peaks eluting were detected by ultraviolet (UV) spectroscopy and high-resolution mass spectrometry (MS).